Eli Lilly and Co

NYSE:LLYUnited States

Eli Lilly and Company is engaged in drug manufacturing businesses. It discovers, develops, manufactures, and markets products in the human pharmaceutical products segment. Its diabetes products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro, and Trulicity. Its oncology products consist of Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, and others. Its immunology products include Olumiant, Taltz, oral IL-17 inhibitors and others. Its neuroscience products include Cymbalta, Emgality, and Zyprexa. Its other therapies consist of Bamlanivimab and etesevimab, Bebtelovimab and Forteo. It maintains special business groups for service wholesalers, pharmacy benefit managers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. It manufactures and distributes its products through facilities in the United States, including Puerto Rico, and other countries. Its products are sold in over 110 countries.

Contact Information

Headquarters

Lilly Corporate Ctr Drop Code 1094, Lilly Corporate CtrINDIANAPOLIS, IN, United States 46285-0001

Phone

317-276-2000

Fax

317-276-3492

Executives

Chairman of the Board, President, Chief Executive Officer

David Ricks

Chief Financial Officer, Executive Vice President

Anat Ashkenazi

Executive Vice President, Chief Information and Digital Officer

Diogo Rau

Chief Scientific Officer, President of Lilly Research Laboratories, President of Lilly Immunology

Daniel Skovronsky

Executive Vice President - Enterprise Risk Management, Chief Ethics and Compliance Officer

Alonzo Weems